Navigation Links
St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

amivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

    Contact:

    BioCryst Pharmaceuticals, Inc.

    Jonathan M. Nugent

    V.P. Corporate Communications

    (205) 444-4633

CONTACT: Jonathan M. Nugent, V.P. Corporate Communications of BioCrystPharmaceuticals, Inc., +1-205-444-4633

Web site: http://www.biocryst.com/'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/21/2015)... , May 21, 2015 ... the addition of the "North American Active ... by Application (Surgical Wound, & Ulcer), by End-User ... 2019" report to their offering. ,     (Logo: ... market is estimated to grow at a CAGR ...
(Date:5/21/2015)... -- Cardica, Inc. (Nasdaq: CRDC ) today announced that on ... company,s vice president of operations, was granted an option to ... per share exercise price of $0.43, the closing trading price ... to Cardica, Inc.,s Inducement Plan, which was approved by the ... of the Nasdaq Global Market for equity grants to induce ...
(Date:5/21/2015)... CAMBRIDGE, England , May 21, ... zur Bekämpfung von Arzneimittelfälschungen - Zwecks ... eines Arzneimittelprüfdienstes wird auf EG-Mitgliedstaaten verwiesen, ... Pilotsysteme betrieben werden.  Wählen Sie ein ... Bei der Richtlinie zur Bekämpfung von ...
Breaking Medicine Technology:North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 2EU-Arzneimittel-Richtlinie für gefälschte Medikamente; Aegate-Zusammenfassung als reale Bewertung aus Belgien 3
... The U.S. Food and Drug Administration today issued new ... needle-free clinical devices to administer influenza vaccinations. Based on ... ) immediately discontinued use of such clinical devices at ... The Kroger family of pharmacies and The Little ...
... HAYWARD, Calif., Oct. 21, 2011 Intarcia ... a letter of intent with Quintiles , the world,s ... 3 program for Intarcia,s ITCA 650 (DUROS® subcutaneous continuous delivery ... GLP-1 therapy to better address the unmet needs of the ...
Cached Medicine Technology:Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes 2Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes 3Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes 4
(Date:5/22/2015)... 22, 2015 Combination therapy, or ... for chronic obstructive pulmonary disorder (COPD) as the ... AstraZeneca plc as well as Germany’s Boehringer Ingelheim ... position. But will market payers, clinicians and patients ... products to completely new ones? , In spite ...
(Date:5/22/2015)... Coordinating care for people with ... providers have not been reimbursed or rewarded for ... Medicare has paved the way by offering reimbursement ... launch of Oculus Health , an innovative ... the platform will now be able to easily ...
(Date:5/22/2015)... 22, 2015 ZH Healthcare ... solutions, announced today that Bill Lane, joins ZH’s ... developer of BlueEHS,a first of its kind, Freemium ... customizable Electronic Health Records (EHR) with an integrated ... telemedicine-enabled comprehensive patient portal, and more. Combined with ...
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the opening of ... 16th sweetFrog store located in the Lone Star State. The ... Inc. 500 list of fastest growing companies in 2014. ... for 20 years and love the natural beauty and friendly ... Palestine, sweetFrog locations. “We are really excited about giving back ...
(Date:5/22/2015)... May 22, 2015 In an effort ... and Sons is offering to donate $5 dollars for ... AC unit or water softening system. Customers have their ... and Sons gets business; and the Special Olympics receives ... Special Olympics helps over 4.4 million athletes, and boasts ...
Breaking Medicine News(10 mins):Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2
... 2010) -- Nine-year-old Morgan LaRue is the first cancer patient ... magnetically lengthen her leg, sparing her the possibility of up ... and extension took place at Texas Children,s Cancer Center in ... Center or the device, please see http://bit.ly/MorganLaRue ., On ...
... a year in U.S., Canada, study says , FRIDAY, ... in public places across the United States and Canada ... otherwise would die of cardiac arrest each year, researchers ... for defibrillators in more limited setting, such as casinos ...
... movement, quality of life, researchers say , FRIDAY, April 16 ... small but significant improvements in their ability to move their ... finds. , The study, by the U.S. Department of ... New England Journal of Medicine , offers the strongest evidence ...
... ... in the body. , ... PA (Vocus) April 16, 2010 -- Researchers at Drexel University College of Medicine ... in breast cancer cells and is critical for cancer growth and movement. When researchers reduced ...
... ... 2010 targets in the fight against the disease, World Vision’s End Malaria campaign is leading ... to press American congressional leaders to keep investing in programs that are saving the lives ... ...
... ... Onyx M.D., announces that they now help physicians find government physician jobs as they ... agencies which provides a new source of locum tenens or temporary physician job opportunities ... ...
Cached Medicine News:Health News:Texas Children's Cancer Center first in Texas to magnetically lengthen 9-year-old's leg as she grows 2Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Robot-Aided Therapy Can Help Patients Years After Stroke 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 2Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 3Health News:Onyx M.D. Awarded GSA Schedule Contract Creating Increases Access to Government Physician Jobs 2Health News:Onyx M.D. Awarded GSA Schedule Contract Creating Increases Access to Government Physician Jobs 3
Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
... Helmer presents the i.Series ... innovative solutions for the ... sophisticated features than ever ... Refrigerators are at the ...
... Designed for the precise requirements of ... Forma Blood Bank Equipment meets American ... National Red Cross (ANRC) and U.S. ... Refrigerators, storage freezers, and platelet incubators ...
... Designed for the precise requirements of ... Forma Blood Bank Equipment meets American ... National Red Cross (ANRC) and U.S. ... Refrigerators, storage freezers, and platelet incubators ...
Medicine Products: